$SPHS (Sophiris Bio, Inc.)

$SPHS {{ '2016-08-29T09:54:58+0000' | timeago}} • Announcement

$SPHS will also use proceeds from the offering for working capital and corporate purposes, which may include R&D, G&A, and manufacturing expenses, and monthly principal and interest payments to Oxford Financial. Company believes its cash, cash equivalents and investments, together with the proceeds, will fund its operations into at least 2Q18.

$LGND {{ '2018-01-11T17:54:53+0000' | timeago}} • Announcement

Pharma company $LGND has signed a license agreement with Glenmark Pharmaceuticals, allowing the latter to use the OmniAb platform for discovery of antibodies. For products incorporating OmniAb antibodies, Ligand will receive annual platform access payments and royalties, while the programs will be entirely funded by Glenmark.

$LGND {{ '2018-01-03T14:25:12+0000' | timeago}} • Announcement

$LGND's partner HanAll Biopharma out-licensed antibody projects that were discovered by HanAll using $LGND’s OmniAb antibody discovery platform. The licensing events triggered $6MM of payments to $LGND. Including these payments, $LGND now anticipates total revenue for full year 2017 to be approx. $140MM with adjusted EPS to be $3.13-3.16.

$LMNX {{ '2017-12-13T22:09:07+0000' | timeago}} • Announcement

$LMNX declared a cash dividend for 4Q17 of $0.06 per share of common stock payable on January 12, 2018 to stockholders of record on December 22, 2017.

$MGLN {{ '2017-10-09T12:21:46+0000' | timeago}} • Announcement

$MGLN has received all necessary regulatory approvals to acquire Senior Whole Health, a healthcare company focused on serving complex, high-risk population. Magellan now expects closing on or before Dec 31, 2017.

$LGND {{ '2017-10-04T20:35:46+0000' | timeago}} • Announcement

$LGND agreed to buy Crystal Bioscience Inc. Crystal non-cash amortization expense estimates are expected to be determined in the near term. Including this acquisition, $LGND now sees 2017 total revenues to be at least $134MM, with potential for additional $9MM of contract payments, and adjusted EPS of about $2.93.

$LGND {{ '2017-10-04T20:34:48+0000' | timeago}} • Announcement

$LGND agreed to buy Crystal Bioscience Inc. This acquisition is projected to contribute up to $1MM of revenue and a similar level of operating expenses during 4Q17. For 2018, $LGND expects incremental Crystal revenues of at least $5MM and incremental EPS of at least $0.09.

$LGND {{ '2017-10-04T20:33:36+0000' | timeago}} • Announcement

$LGND agreed to buy Crystal Bioscience Inc. $LGND will pay Crystal shareholders $25MM in cash at closing, up to an additional $10.5MM of success-based milestones, and revenue sharing from existing licensees for a defined period.

$MGLN {{ '2017-09-25T11:21:06+0000' | timeago}} • Announcement

$MGLN has completed a public offering of $400MM aggregate principal amount of its 4.40% senior notes due 2024. The notes were issued on Sept 22, 2017 at a public offering price of 99.8%. The net proceeds were approx $394.7MM after deducting underwriting discounts and estimated offering expenses.

$LMNX {{ '2017-09-12T12:54:37+0000' | timeago}} • Announcement

The BoD of $LMNX has declared a cash dividend of $0.06 per share of common stock for 3Q17, payable on Oct 13, 2017 to stockholders of record as on Sept 22, 2017.

$LMNX {{ '2017-08-29T13:23:43+0000' | timeago}} • Announcement

$LMNX has entered into a collaboration with Sutter Health, a not-for-profit health system. The partnership offers the service of Luminex's molecular diagnostic systems at Sutter Health Shared Laboratory, for processing lab samples from the latter’s health network. It is expected to facilitate effective diagnosis of various health problems.

$LGND {{ '2017-08-21T14:07:20+0000' | timeago}} • Announcement

$LGND appointed Nancy Ryan Gray to its BoD, effective Aug 21, 2017. Dr Gray currently serves as CEO of Gordon Research Conferences, a not-for-profit organization that arranges conferences in the biological, chemical, and physical sciences worldwide.

$LGND {{ '2017-08-18T14:40:01+0000' | timeago}} • Announcement

$LGND will receive a $2MM payment from WuXi Biologics subsequent to their licensing of exclusive rights to the anti-PD-1 antibody GLS-010 to Arcus Biosciences in North America, Europe, Japan and certain other territories. $LGND is also entitled to future milestones and royalties from this antibody.

$LMNX {{ '2017-07-24T14:45:10+0000' | timeago}} • Announcement

$LMNX has received FDA clearance for its Aries C. difficile Assay, a method for rapid detection of toxigenic agents. The Aries system is designed to run in multiple laboratory shifts.

$MGLN {{ '2017-07-13T12:33:15+0000' | timeago}} • Announcement

Health care company $MGLN has entered into a definitive agreement to acquire Senior Whole Health (SWH) for $400MM cash, inclusive of $10MM contingent payment. $MGLN anticipates paying the purchase price from the proceeds of new debt offerings. The company expects to close the transaction by end of the 1Q18.

$LGND {{ '2017-06-20T13:57:42+0000' | timeago}} • Announcement

$LGND's partner Melinta Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved the delafloxacin drug Baxdela, indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria.

$LGND {{ '2017-06-20T13:19:53+0000' | timeago}} • Announcement

$LGND's partner Melinta Therapeutics said the FDA has approved Baxdela (delafloxacin), indicated in adults for the treatment of acute bacterial skin and skin structure infections caused by susceptible bacteria.

$LGND {{ '2017-06-01T16:46:36+0000' | timeago}} • Announcement

$LGND entered into a worldwide license agreement with Cambridge, Massachusetts-based Surface Oncology. Surface will be able to use the OmniRat, OmniMouse and OmniFlic platforms to discover fully human mono- and bispecific antibodies. Surface will be responsible for all costs related to the programs.

$LGND {{ '2017-06-01T11:46:02+0000' | timeago}} • Announcement

$LGND expects the additional revenue to be classified as contract revenue and royalty revenue to be slightly lower for the full year due to lower royalty rate on CorMatrix products beginning with 2H17. Additional upside in contract revenue guidance is lowered from $24MM to $14MM, on revenue from royalty rate buy-down and associated amortization.

$LGND {{ '2017-06-01T11:44:39+0000' | timeago}} • Announcement

$LGND said it will book an estimated $2MM of additional revenue in 2017, net of offsetting non-cash accounting expenses. Previous net revenue guidance for 2017 was at least $130MM, and $LGND now expects 2017 net revenue to increase to at least $132MM. This implies minimum adjusted EPS for 2017 of $2.90, up from prior estimate of at least $2.70.

$LGND {{ '2017-06-01T11:43:01+0000' | timeago}} • Announcement

$LGND said it will receive $10MM from a contractually specified royalty rate buy-down after the sale by CorMatrix Cardiovascular of rights to its commercial pericardial repair and CanGaroo Envelope extracellular matrix (ECM) products to Aziyo Biologics. In May 2016, $LGND acquired rights to royalties on these products from CorMatrix for $17.5MM.

Recent Transcripts

CGIX (Cancer Genetics, Inc.)
Thursday, November 9 2017 - 1:30pm
LFVN (Lifevantage Corporation)
Wednesday, November 8 2017 - 9:30pm
MGNX (MacroGenics, Inc.)
Wednesday, November 8 2017 - 9:30pm
LXRX (Lexicon Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 3:00pm
MNKD (MannKind Corp.)
Tuesday, November 7 2017 - 10:00pm
KIN (Kindred Biosciences, Inc.)
Tuesday, November 7 2017 - 9:30pm
KERX (Keryx Biopharmaceuticals Inc.)
Monday, November 6 2017 - 10:00pm
KPTI (Karyopharm Therapeutics, Inc.)
Thursday, November 2 2017 - 12:30pm
MGLN (Magellan Health, Inc.)
Wednesday, November 1 2017 - 2:00pm
LMNX (Luminex Corporation)
Monday, October 30 2017 - 8:30pm
LFVN (Lifevantage Corporation)
Thursday, September 7 2017 - 8:30pm
CGIX (Cancer Genetics, Inc.)
Monday, August 14 2017 - 9:00pm
KPTI (Karyopharm Therapeutics, Inc.)
Tuesday, August 8 2017 - 12:30pm
MNKD (MannKind Corp.)
Monday, August 7 2017 - 9:00pm
LMNX (Luminex Corporation)
Monday, August 7 2017 - 8:30pm
KIN (Kindred Biosciences, Inc.)
Monday, August 7 2017 - 8:30pm
LGND (Ligand Pharmaceuticals Incorporated)
Monday, August 7 2017 - 8:30pm
MGNX (MacroGenics, Inc.)
Wednesday, August 2 2017 - 8:30pm
LXRX (Lexicon Pharmaceuticals, Inc.)
Tuesday, August 1 2017 - 12:00pm
MGLN (Magellan Health, Inc.)
Friday, July 28 2017 - 12:30pm

AlphaGraphics you may like